Slaski Park Technologii Medycznych Kardio-Med Silesia

The Silesian Park of Medical Technologies Kardio-Med Silesia (KMS) is the owner of the Laboratories and Research Center for Personalized Medicine and Bioregeneration, which was established on the initiative of Professor Marian Zembala, an outstanding Polish doctor specializing in cardiac surgery, transplantology, and former Minister of Health RP. KMS is prepared to carry out research from the level of: discovery, preclinical research (in vitro research: various models of cellular research, including research using stem cells and in vivo research: research in models: mice, rat, rabbit, guinea pig, hamster, classic pig, minipig and sheep) and clinical trials with patients. KMS meets...

Healthcare,glp,medicine,biotechnology,medical technology,cells,cell-based research,stem cell,in vitro studies,in vivo studies,bio-printing,3d printing,research in small and large animal models,biocompatibility in vitro,biocompatibility in vivo,toxicity studies,biotech,medtech,regenerative medicine,personalised medicine ,and ophthalmology

Slaski park technologii medycznych kardio-med silesia operates in the Biotechnology research industry.

Slaski park technologii medycznych kardio-med silesia's revenue is 11m - 100m

Slaski park technologii medycznych kardio-med silesia has 11 - 50 employees.